Table 1.
Baseline characteristics
| All N = 341 | LSD N = 82 | MSD N = 116 | HSD N = 143 | P value | |
|---|---|---|---|---|---|
| Age years, mean (SD) | 64.4 (14.9) | 68.4 (15.1) β | 66.9 (15.4) | 60.1 (13.2)μ | <0.05 |
| Female, n (%) | 128 (37.5) | 35 (42.7) | 46 (39.7) | 47 (32.9) | 0.29 |
| MAP mm Hg, mean (SD) | 111 (14.2) | 111 (14.1) | 114 (15.1) | 112 (13.5) | 0.36 |
| BMI kg/m2, mean (SD) | 29.9 (6.6) | 25.3 (4.1) α, β | 28.6 (4.8) μ, | 33.7 (7.0) | <0.05 |
| eGFR ml/min/1.73 m2 mean, (SD) | 17.1 (5.5) | 16.4 (4.1) | 18.0 (6.7) | 16.7 (5.2) | 0.30 |
| Urine protein, g/day median, (IQR) | 1.5 (2.7) | 1.0 (2.1) α, β | 1.3 (1.9) | 1.9 (3.4) | <0.05 |
| Cause of CKD, n (%) | |||||
| Diabetic nephropathy | 162 (47.5) | 27 (32.9) | 50 (43.1) | 85 (59.4) | 0.06 |
| Ischemic nephropathy | 61 (17.9) | 21 (25,6) | 21 (18.1) | 19 (13.3) | 0.16 |
| Glomerulonephritis | 43 (12.7) | 14 (17.1) | 16 (13.8) | 13 (9.1) | 0.29 |
| PCKD | 27 (8) | 8 (9.6) | 10 (8.6) | 9 (6.3) | 0.67 |
| Other | 48 (14.1) | 12 (14.6) | 19 (16.4) | 17 (11.9) | 0.66 |
| Comorbidities, n (%) | |||||
| Diabetes | 198 (58.2) | 32 (39) | 61 (52.6) | 105 (73.4) | 0.02 |
| CAD | 105 (30.8) | 20 (24.4) | 35 (30.2) | 50 (35.0) | 0.48 |
| CHF | 79 (23.2) | 13 (15.9) | 22 (19) | 44 (30.8) | 0.08 |
| Hypertension | 319 (93.6) | 76 (92.7) | 109 (94) | 134 (93.7) | 0.99 |
| CVA | 36 (10.6) | 7 (8.5) | 12 (10.3) | 17 (11.9) | 0.78 |
| Dyslilidemia | 235 (68.9) | 50 (61) | 81 (69.8) | 104 (72.7) | 0.72 |
| Medications, n (%) | |||||
| RAS blocker | 181 (53.1) | 40 (48.8) | 64 (55.2) | 77 (53.9) | 0.88 |
| Diuretic | 219 (64.2) | 48 (58.5) | 76 (65.5) | 95 (66.4) | 0.84 |
| Calcium channel blockers | 237 (69.5) | 53 (64.6) | 87 (75) | 97 (67.8) | 0.78 |
| Beta blockers | 178 (52.2) | 38 (46.3) | 62 (53.4) | 78 (54.5) | 0.78 |
SD standard deviation, IQR interquartile range, MAP mean arterial blood pressure, BMI body mass index, eGFR estimated glomerular filtration rate, PCKD polycystic kidney disease, CAD coronary artery disease, CHF congestive heart failure, CVA cerebrovascular accident, RAS renin-angiotensin system
αP < 0.05 between LSD and MSD
βP < 0.05 between LSD and HSD
μP < 0.05 between MSD and HSD